Clinical Trial Results:
Prospektive, offene Studie zur Prüfung der Wirksamkeit der zusätzlichen Gabe des Somatostatinanalogon Octreotid (Sandostatin) bzw. des Dopaminagonisten Cabergolin (Dostinex) bei Patientin mit Akromegalie unter laufender Therapie mit Pegvisomant (Somavert);
Prospective, open-label study to evaluate the efficacy of the combined treatment of somatostatin analogue octreotide (Sandostatin) or dopamine agonist cabergoline (Dostinex) in patients with acromegaly on stable therapy of pegvisomant (Somavert).
Summary
|
|
EudraCT number |
2007-005585-12 |
Trial protocol |
DE |
Global completion date |
15 Jul 2009
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
29 Mar 2020
|
First version publication date |
29 Mar 2020
|
Other versions |
|
Summary report(s) |
Results |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.